Literature DB >> 6854035

Enzyme-linked immunosorbent assay (ELISA) for antibodies to Clostridium difficile toxins in patients with pseudomembranous colitis and antibiotic-associated diarrhoea.

B Aronsson, M Granström, R Möllby, C E Nord.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) was established with purified toxins from Clostridium difficile as antigen to measure antibody response in patients with pseudomembranous colitis (PMC) and prolonged antibiotic-associated diarrhoea (AAD). Positive ELISA titres were defined in a control population. Antibodies of IgG class against toxin B were demonstrated in 6/88 (7%) control sera and in 31/61 (51%) sera from 11/19 (58%) patients. Antibodies of IgA class were found in one patient while antibodies of IgM class were not demonstrated. ELISA antibodies against toxin A were not demonstrated. For comparison a neutralization test was performed and neutralizing antibodies to toxin B but not to toxin A were demonstrated in 10/61 (16%) sera from 4/19 (21%) patients and in none of the controls. ELISA was found to be a more sensitive assay than neutralization. ELISA antibodies were detected from the third week of the disease while neutralizing antibodies appeared after 5 weeks. Lack of an antibody response in ELISA seemed to correlate to a more severe colitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6854035     DOI: 10.1016/0022-1759(83)90291-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

Review 1.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

2.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

3.  Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea.

Authors:  A Pantosti; M Cerquetti; F Viti; G Ortisi; P Mastrantonio
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

4.  Antibody response of infected mice to outer membrane proteins of Pseudomonas aeruginosa.

Authors:  R C Hedstrom; O R Pavlovskis; D R Galloway
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

5.  Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

Authors:  C P Kelly; C Pothoulakis; F Vavva; I Castagliuolo; E F Bostwick; J C O'Keane; S Keates; J T LaMont
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Low levels of coagulation inhibitors in patients with Clostridium difficile infection.

Authors:  B Aronsson; M Blombäck; S Eriksson; N Egberg
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

7.  Enzyme immunoassay for detection of Clostridium difficile toxins A and B in patients with antibiotic-associated diarrhoea and colitis.

Authors:  B Aronsson; M Granström; R Möllby; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

8.  Nosocomial diarrhoeas in a surgical division hyperendemic for Clostridium difficile: epidemiologic aspects emerging from an analysis of clinical records.

Authors:  P Urbano; S Le Brun
Journal:  Eur J Epidemiol       Date:  1986-12       Impact factor: 8.082

9.  Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea.

Authors:  B Aronsson; M Granström; R Möllby; C E Nord
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.